Related Articles
2 November 2021
OncoResponse Announces Initiation of Phase 1 Trial of OR2805 – Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy – in Patients with Advanced Cancer
6 October 2021
OncoResponse Announces Presentations at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021)
7 July 2021
ONCORESPONSE APPOINTS SEAN McCARTHY TO BOARD
OF DIRECTORS
11 May 2021
OncoResponse Appoints Chris Russell as Chief Financial Officer
31 March 2021
OncoResponse Raises $40.6 Million Series C Financing
14 April 2020
OncoResponse Appoints Robert Lechleider, MD as Chief Medical Officer; Promotes Kamal Puri, PhD to Chief Scientific Officer
10 October 2016
HELSINN INVESTMENT FUND TO INVEST $3.5M IN ONCORESPONSE
Get in touch
Thank you for your form submission, we will get in contact with you shortly.
